| Autor: |
Tamila V, Sorokman, Snizhana V, Sokolnyk, Pavlo M, Moldovan, Nadiia Ya, Chernei, Valentuna G, Ostapchuk |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Wiadomosci lekarskie (Warsaw, Poland : 1960). 75(1 pt 2) |
| ISSN: |
0043-5147 |
| Popis: |
The aim: To evaluate the efficacy of the drug VitD children with H.pylori-associated duodenal ulcer.Materials and methods: Two treatment groups of children with DU were formed: I - 60 children with H. pylori-associated DU, who received the optimal scheme of anti- Helicobacter therapy (AHBT) for Chernivtsi region; II - 62 children with H. pylori-associated DU who received a modified treatment regimen: AGBT + VitD at a dose of 2000 IU / day for 1 month. The effectiveness of the treatment was evaluated taking into account the Relative Risk Reduction (RRR) of the adverse event and Number Needed to Treat (NNT).Results: All children with DU and a positive H. pylori infection test showed changes in serum VitD levels: 81.9% deficiency and 18.1% insufficiency. Successful eradication was achieved in 77.1% of children, in particular in the first group 73.3%, in the second - 82.2%. Predictors of successful eradication are the duration of infection, H. pylori CagA (+), VitD level. When using the VitD treatment regimen in children with DU associated with CagA (+) strain H.pylori, RRR was observed 2.29 times (χ2 = 6.34, pφ0.05) with NNT 1.59.Conclusions: Due to the reduced level of serum VitD in children with H. pylori-associated DU, it is advisable to include in the treatment regimen the adjuvant component of AHBT in the form of VitD. Predictors of effective eradication of H. pylori are CagA (+) strain of H. pylori, duration of infection and VitD level. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
